Skip to content
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
our mission

TriSalus Life Sciences® seeks to extend and improve the lives of patients living with liver and pancreatic tumors.

Illustration of the two organs, two problems, two solutions approach that TriSalus is working on. Two organs: the liver and pancreas in an elderly, male patient. Addressing two problems: immunosuppression and tumor pressure which causes blood vessel collapse. Combining two solutions: immunotherapy via pressure enabled drug delivery.
Addressing two problems: immunosuppression and tumor pressure which causes blood vessel collapse.
Combining two solutions: immunotherapy via pressure enabled drug delivery.

We’re developing a transformative platform to address barriers to the treatment of liver and pancreatic tumors.

Two critical barriers, intratumoral pressure and an immunosuppressive environment, limit the delivery and efficacy of immunotherapies in tumors of the liver and pancreas.

We believe that comprehensively addressing these two barriers has the potential to improve the lives of patients with liver and pancreatic tumors. Our therapeutic platform is designed to be used in combination with, and enable, systemic immunotherapies like checkpoint inhibitors.

Our Science

Learn about how TriSalus aims to address two of the most significant barriers to treatment.

 

  • Science
Video Thumbnail with text: Prologue
Play Video about Video Title Slide: Prologue
See Our Platform in Action

TriSalus takes an integrated approach tailored to the target organ and disease biology, with the goal to overcome two critical barriers: immunosuppression and delivery.

Watch to learn how our platform approach applies to the treatment of liver tumors.

  • Platform

Share video

  • view current job openings

Recent News

TriSalus Life Sciences to Showcase Treatment Platform and Present Pressure-Enabled Regional Immuno-Oncology (PERIO) Data at the Society of Interventional Radiology’s 2023 Annual Scientific Meeting

February 28, 2023

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

February 21, 2023

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

February 16, 2023

Our Pipeline

We’re studying the integration of the Pressure-Enabled Drug Delivery™ (PEDD™) method with therapies capable of reactivating immune cells to enable immunotherapies in the liver and pancreas. Our clinical research is focused on bringing this potentially transformative treatment platform to patients.

PIPELINE
© 2023 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL